Investor-Grade Deep Dive Research Report
March 2026
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Irvine, California, focused on developing and commercializing novel therapeutics for eye care and infectious diseases. Founded in 2016, the company has rapidly evolved from clinical-stage to a high-growth commercial entity with its FDA-approved flagship product XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only approved treatment for Demodex blepharitis affecting approximately 25 million Americans.
Tarsus occupies a unique monopoly position as the developer of XDEMVY, creating a new treatment category by targeting the root cause (Demodex mites) of a previously under-treated chronic eyelid condition. Key competitive advantages include:
| Metric | Value | YoY Change |
|---|---|---|
| Net Product Sales | $451.4 million | +150.6% |
| Q4 2025 Net Sales | $151.7 million | +128.4% |
| Operating Expenses | $522.3 million | Not disclosed |
| Net Loss (Q4 2025) | $8.37 million | Improved from $23.11M |
| Cash & Equivalents | $418.0 million | Strong position |
| Gross-to-Net Discount | ~45% | Stable |
| Bottles Dispensed (Annual) | ~400,000 | Strong growth |
Note on EBITDA: Tarsus does not publicly report EBITDA or adjusted EBITDA. Based on net product sales of $451.4M and operating expenses of $522.3M, the company is approaching operational break-even with narrowing losses.
| Product | Indication | Status | FY 2025 Revenue | Peak Sales Potential |
|---|---|---|---|---|
| XDEMVY | Demodex blepharitis | Approved (US) | $451.4M | >$2B (US) |
| TP-04 | Ocular rosacea | Phase 2 planned (H2 2025) | $0 | Not disclosed |
| TP-05 | Lyme disease prevention | Phase 2a complete (positive) | $0 | Not disclosed |
| Institution | Holding Value | Est. % Ownership |
|---|---|---|
| RTW Investments LP | $273.10M | ~8.5% |
| Paradigm Biocapital Advisors LP | $209.79M | ~6.5% |
| Vanguard Group Inc. | $196.48M | ~6.1% |
| Toronto Dominion Bank | $105.71M | ~3.3% |
| Jennison Associates LLC | $99.98M | ~3.1% |
| Competitor/Therapy | Type | Strengths | Weaknesses vs. XDEMVY |
|---|---|---|---|
| XDEMVY (Tarsus) | Prescription FDA-approved | Only approved therapy; targets root cause | Higher cost vs. OTC; requires diagnosis |
| Lid Hygiene Products (OTC) | Non-prescription | Low cost; accessible | Symptom relief only; doesn't kill mites |
| Topical Antibiotics | Prescription off-label | Treat bacterial infection | Don't address Demodex; overuse concerns |
| Cyclosporine/Lifitegrast | Prescription (DED drugs) | Treat inflammation/dry eye | Don't kill mites; expensive; chronic use |
Market Position: XDEMVY holds a monopoly as the only FDA-approved Demodex blepharitis therapy with patent exclusivity to December 2038. No Phase 3 competitors identified as of March 2026.
| Metric | Value |
|---|---|
| Market Capitalization | $3.1-3.2 billion |
| Enterprise Value | $1.98 billion (Aug 2025) |
| Share Price (Recent) | $73-76 |
| 52-Week Range | $38.51 - $85.25 |
| Price/Sales (2025) | 7.1x |
| Price/Sales (2026E) | 4.7x |
| Analyst Consensus Rating | Buy |
| Consensus Price Target | $89 (+22% upside) |
Bull Case:
Base Case Fair Value: $100-120/share (30-40% upside from current $73-76)
| Metric | Value |
|---|---|
| Total US Prevalence | 25 million adults |
| Currently Diagnosed/Treated | 1.5 million annually |
| Underdiagnosis Rate | 94% (23.5M undiagnosed) |
| Addressable by Ada | 8.5 million undiagnosed symptomatic patients |
| Net Revenue per Patient (US) | $1,045 (post-rebate) |
| Lifetime Value (3yr) | $2,090 (with retreatment) |
| Ada Finder's Fee (8-12%) | $84-125 per diagnosed patient |
"Close the 94% Diagnostic Gap in Demodex Blepharitis—8.5 Million Undiagnosed Americans Need XDEMVY. Ada's symptom assessment can identify the hallmark triad (eyelid itching, crusting, redness) and triage patients to eye care professionals. With 80% of affected patients reporting significant QOL impact and XDEMVY offering 56% complete cure in 6 weeks, every patient Ada surfaces represents both a life improved and $1,045 in net revenue ($84-125 finder's fee). This is not patient acquisition—it's market expansion into an underserved population already seeking care."
| Product | Indication | US Exclusivity Expiration | Key Patents |
|---|---|---|---|
| XDEMVY | Demodex blepharitis | December 14, 2038 | US11690826, US10835517 (9 active patents total) |
| TP-04 | Ocular rosacea | 2038 (projected) | Lotilaner gel formulation patents |
| TP-05 | Lyme prevention | Not disclosed | Oral lotilaner method-of-use patents |
Key Risk: Generic challenge window opens July 25, 2027 (4-year NCE exclusivity expiration), though actual generic launch unlikely until 2038 patent expiration due to 9 active patents protecting XDEMVY.
Tarsus Pharmaceuticals represents a high-growth commercial-stage biotech with a dominant monopoly position in Demodex blepharitis treatment via XDEMVY. The company has demonstrated exceptional execution with 151% revenue growth in FY 2025, achieving $451.4M in net sales and approaching profitability. With 12+ years of patent exclusivity, >90% payer coverage, and a massive underdiagnosed patient population (25M prevalence, only 1.5M treated), XDEMVY is on track to exceed $2B in peak U.S. sales.
For Ada Health, Tarsus presents the highest-value Patient Finder opportunity identified to date: a 94% diagnostic gap in a highly symptomatic, quality-of-life-impacting condition with clear symptom patterns Ada can surface. With $1,045 net revenue per patient and an 8.5M addressable undiagnosed market, this partnership could drive significant market expansion while improving patient outcomes.
International expansion (Europe, China, Japan) and pipeline advancement (TP-04 for ocular rosacea, TP-05 for Lyme prevention) provide multiple growth vectors and diversification from current single-product concentration. Risks include pipeline execution, regulatory uncertainties, and long-term generic competition, but the near-to-medium term outlook (2026-2030) remains exceptionally strong.
Analyst Consensus: Buy rating with $89 price target (+22% upside from current $73-76), supported by strong fundamentals and clear path to multi-billion-dollar peak sales.